FTRE
HealthcareFortrea Holdings Inc.
$16.62
$-0.19 (-1.13%)
Jan 5, 2026
Price History (1Y)
Analysis
Fortrea Holdings Inc. (FTRE) is a biotechnology company operating in the healthcare sector. With a market capitalization of $1.54B and revenue of $2.76B, it has significant scale, employing approximately 14,500 individuals. The company's financial health is concerning, with negative profitability metrics across the board. The gross margin stands at 18.6%, while the operating margin is -0.5% and profit margin is -36.8%. Returns on equity and assets are also heavily in the red, at -98.1% and -1.3%, respectively. Fortrea Holdings' balance sheet features a substantial debt-to-equity ratio of 204.65, although it does have $131.30M in cash available. The valuation context for Fortrea Holdings is marked by a forward P/E ratio of 21.21, which indicates that investors are willing to pay nearly 22 times the company's expected earnings per share. The revenue growth rate has been positive at 3.9% year-over-year, but it is essential to note that there is no available data on earnings growth. The dividend yield is not applicable due to a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Fortrea Holdings Inc.
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum. The company also offers delivery models that include full service, functional service provider, and hybrid service structures. In addition, it delivers phase I IV clinical trial management, clinical pharmacology, and consulting services. Fortrea Holdings Inc. enters into a strategic collaboration with Emery Pharma to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction studies, to certify impurities are below the Acceptable Intake Limit set by U.S. Food and Drug Administration guidelines. The company has a strategic collaboration with SCT Cell Manufacturing s.r.o. to streamline development, accelerate timelines and bring advanced therapies to patients faster. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Visit website →Key Statistics
- Market Cap
- $1.54B
- P/E Ratio
- N/A
- 52-Week High
- $20.07
- 52-Week Low
- $3.97
- Avg Volume
- 1.28M
- Beta
- 1.57
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 14,500